These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32447231)

  • 21. Addition of propolis to irinotecan therapy prolongs survival in ehrlich ascites tumor-bearing mice.
    Lisičić D; Benković V; Ðikić D; Blažević AS; Mihaljević J; Oršolić N; Knežević AH
    Cancer Biother Radiopharm; 2014 Mar; 29(2):62-9. PubMed ID: 24383762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis.
    Dai J; Chen Y; Gong Y; Wei J; Cui X; Yu H; Zhao W; Gu D; Chen J
    Medicine (Baltimore); 2019 Sep; 98(39):e17384. PubMed ID: 31574891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
    Schmitz D; Kazdal D; Allgäuer M; Trunk M; Vornhusen S; Nahm AM; Doll M; Weingärtner S; Endris V; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Budczies J; Kienle P; Magdeburg R; Hetjens S; Schirmacher P; Bergmann F; Rudi J; Stenzinger A; Volckmar AL
    Genes Chromosomes Cancer; 2021 Jul; 60(7):489-497. PubMed ID: 33686791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
    Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
    Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
    Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis.
    Foster JM; Patel A; Zhang C; Shostrom V; Brown K; Cushman-Vokoun AM
    J Surg Oncol; 2020 Nov; 122(6):1106-1113. PubMed ID: 32662065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.
    Adhoute X; De Matharel M; Mineur L; Pénaranda G; Ouizeman D; Toullec C; Tran A; Castellani P; Rollet A; Oules V; Perrier H; Si Ahmed SN; Bourliere M; Anty R
    World J Gastrointest Oncol; 2022 Aug; 14(8):1510-1527. PubMed ID: 36160737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
    Wen F; Zheng H; Zhang P; Zhou J; Chen H; Zhou K; Li Q; Bi F
    Eur J Cancer Care (Engl); 2020 Jan; 29(1):e13196. PubMed ID: 31825141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
    Pietrantonio F; Berenato R; Maggi C; Caporale M; Milione M; Perrone F; Tamborini E; Baratti D; Kusamura S; Mariani L; Niger M; Mennitto A; Gloghini A; Bossi I; Settanni G; Busico A; Bagnoli PF; Di Bartolomeo M; Deraco M; de Braud F
    J Transl Med; 2016 May; 14(1):125. PubMed ID: 27154293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.
    Shen JP; Yousef AM; Zeineddine FA; Zeineddine MA; Tidwell RS; Beaty KA; Scofield LC; Rafeeq S; Hornstein N; Lano E; Eng C; Matamoros A; Foo WC; Uppal A; Scally C; Mansfield P; Taggart M; Raghav KP; Overman MJ; Fournier K
    JAMA Netw Open; 2023 Jun; 6(6):e2316161. PubMed ID: 37261831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
    Takahashi S; Sakamoto Y; Denda T; Takashima A; Komatsu Y; Nakamura M; Ohori H; Yamaguchi T; Kobayashi Y; Baba H; Kotake M; Amagai K; Kondo H; Shimada K; Sato A; Yuki S; Okita A; Ouchi K; Komine K; Watanabe M; Morita S; Ishioka C
    Cancer Sci; 2021 Apr; 112(4):1567-1578. PubMed ID: 33548159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
    Petrelli F; Inno A; Ghidini A; Rimassa L; Tomasello G; Labianca R; Barni S;
    Eur J Cancer; 2017 Aug; 81():174-182. PubMed ID: 28633088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.
    Zhu G; Zhao M; Han Q; Tan Y; Sun YU; Bouvet M; Singh SR; Ye J; Hoffman RM
    Anticancer Res; 2019 Nov; 39(11):5999-6005. PubMed ID: 31704825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
    Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.